237 related articles for article (PubMed ID: 20824460)
1. Creating a European Union framework for actions in the field of rare diseases.
Moliner AM
Adv Exp Med Biol; 2010; 686():457-73. PubMed ID: 20824460
[TBL] [Abstract][Full Text] [Related]
2. The European Union Policy in the Field of Rare Diseases.
Moliner AM; Waligora J
Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
[TBL] [Abstract][Full Text] [Related]
3. The European union policy in the field of rare diseases.
Montserrat Moliner A; Waligóra J
Public Health Genomics; 2013; 16(6):268-77. PubMed ID: 24503587
[TBL] [Abstract][Full Text] [Related]
4. [Hungarian national plan and strategy for rare diseases].
Kosztolányi G
Orv Hetil; 2014 Mar; 155(9):325-8. PubMed ID: 24566695
[TBL] [Abstract][Full Text] [Related]
5. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
6. Policies and actions to tackle rare diseases at European level.
Montserrat A; Taruscio D
Ann Ist Super Sanita; 2019; 55(3):296-304. PubMed ID: 31553326
[TBL] [Abstract][Full Text] [Related]
7. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
8. Legal assessment of current situation on orphan patients in Lithuania.
Spokiene I
Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
[TBL] [Abstract][Full Text] [Related]
9. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
10. Tackling rare diseases at European level: why do we need a harmonized framework?
Taruscio D; Trama A; Stefanov R
Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
[TBL] [Abstract][Full Text] [Related]
11. Rare disease policies to improve care for patients in Europe.
Rodwell C; Aymé S
Biochim Biophys Acta; 2015 Oct; 1852(10 Pt B):2329-35. PubMed ID: 25725454
[TBL] [Abstract][Full Text] [Related]
12. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
13. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
14. Rare diseases and orphan drugs.
Taruscio D; Capozzoli F; Frank C
Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
[TBL] [Abstract][Full Text] [Related]
15. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
16. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
17. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
18. Rare Diseases in Europe: from a Wide to a Local Perspective.
Baldovino S; Moliner AM; Taruscio D; Daina E; Roccatello D
Isr Med Assoc J; 2016 Jun; 18(6):359-63. PubMed ID: 27468531
[TBL] [Abstract][Full Text] [Related]
19. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
Tiwari J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
[TBL] [Abstract][Full Text] [Related]
20. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
